← Back to results

Posted · RFA-DK-27-147

Single Source for Continuation of the Integrated Islet Distribution Program U24 (Clinical Trial Not Allowed)

National Institutes of Health  ·  HHS

CFDA Numbers

93.847

Award Ceiling

$2.2M

Award Floor

Expected Awards

1

Close Date

Sep 30, 2026

Section I

How to Apply

View on grants_gov ↗

Program Contact

Division of Diabetes, Endocrinology and Metabolic Diseases<br/>NIDDK_DEM@nih.gov
NIDDK_DEM@nih.gov

Section II

Eligibility

Only the PI/PDs associated with the award issued under RFA-DK-20-509 to Beckman Research Institute/City of Hope is eligible to apply for this single source funding. Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/Foreign Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.

Eligible Applicant Types

25

Section III

Description

This is a NOFO for a Single Source competition that will invite application(s) from eligible organization(s) to apply. Please see Eligibility Section for additional information. In accordance with NIH standard peer-review processes, the application(s) will be peer-reviewed, and only meritorious application(s) will be considered for funding.The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is announcing its intent to issue a single source cooperative agreement award to Beckman Research Institute/City of Hope for the currently funded Integrated Islet Distribution Program (IIDP) to renew the program and maintain support for its continuing mission to provide the scientific community with important islet resources for diabetes research. The IIDP facilitates the distribution of human islets to biomedical researchers by establishing partnerships with qualified islet isolation facilities to prepare and distribute human islets. Human islets remain an essential resource for diabetes research to advance our understanding of human islet cell biology, and to promote the development of new therapies for the prevention and treatment of diabetes.This NOFO is associated with the Special Diabetes Program (https://www.niddk.nih.gov/about-niddk/research-areas/diabetes/type-1-diabetes-special-statutory-funding-program/about-special-diabetes-program) which funds research on the prevention, treatment, and cure of type 1 diabetes and its complications, including unique, innovative, and collaborative research consortia and clinical trials networks.

Section IV

Key Dates

Posted
May 20, 2026
Closes
Sep 30, 2026
Archive
Nov 29, 2026